检验医学 ›› 2014, Vol. 29 ›› Issue (7): 733-737.DOI: 10.3969/j.issn.1673-8640.2014.07.010

• 临床应用研究·论著 • 上一篇    下一篇

EDTA依赖性假性血小板减少的实验室解决思路

常菁华1,王剑飚2   

  1. 1.上海交通大学医学院附属瑞金医院药剂科,上海 200025;
    2.上海交通大学医学院附属瑞金医院检验科,上海 200025
  • 收稿日期:2014-04-25 出版日期:2014-07-30 发布日期:2014-07-21
  • 通讯作者: 王剑飚,联系电话:021-64370045。
  • 作者简介:常菁华,女,1979年生,主管药师,主要从事临床药物不良反应研究。

Laboratory solutions for EDTA-dependent pseudothrombocytopenia

CHANG Jinghua1,WANG Jianbiao2.   

  1. 1.Department of Pharmacy, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China;
    2. Department of Clinical Laboratory, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025
  • Received:2014-04-25 Online:2014-07-30 Published:2014-07-21

摘要:

目的 探讨乙二胺四乙酸(EDTA)依赖性假性血小板减少的临床解决思路。方法 采集5EDTA依赖性假性血小板减少患者的EDTA及枸橼酸钠抗凝血,每位患者的EDTA-K2抗凝血均在不同时间段分别加入6.5 mg/mL阿米卡星,并依次采用血液分析仪检测及血涂片检查。结果 3例患者在抽血前或抽血后1.5 h内在其EDTA抗凝血中加入阿米卡星后能在不影响其它血细胞形态和分布的情况下解离凝集血小板,其血小板计数能在室温下4 h之内维持稳定。余下2例患者,加或不加阿米卡星,其血小板数均会随着时间的延长逐渐增加,最终基本恢复正常水平,阿米卡星起到加速作用。结论 添加阿米卡星的血小板检测结果在4 h保持稳定,结果明显优于更换枸橼酸钠抗凝剂。该药在医院抗菌药物中使用普遍,且在临床实际工作中,可以减少患者重复采血,缩短报告等候时间。阿米卡星可作为处理EDTA依赖的假性血小板减少的一线方法在临床普及。

关键词: 假性血小板减少, 抗凝剂, 阿米卡星

Abstract:

Objective To study on the laboratory solutions for ethylenediaminetetraacetic acidEDTA-dependent pseudothrombocytopenia. Methods A total of 5 patients with EDTA-dependent pseudothrombocytopenia were enrolled and each blood with EDTA-K2 anticoagulant was added to 6.5 mg/mL amikacin in different time periods. The blood routine test and blood smears were performed. Results In 3 patients before collecting blood or collecting blood after 1.5h its inherent EDTA anticoagulant was added amikacin which can not affect the situation of other blood cell morphology and distribution of dissociation platelet aggregation and the platelet count can be stable within 4h at room temperature. In the other 2 patients with or without amikacin the platelet count increased gradually with time and eventually returned to normal levels and amikacin played acceleration role. Conclusions The test results of platelet adding amikacin in 4h are stable and reliable and the drug use of antibiotics in hospitals is general. In clinical practice it can reduce the duplication of collecting blood and shorten turn-around-time. Amikacin should be as first-line approach in the treatment of EDTA-dependent pseudothrombocytopenia.

Key words: Pseudothrombocytopenia, Anticoagulant, Amikacin

中图分类号: